Kiprop-C Tablet is a combination medication containing Clonazepam 0.5 mg and Propranolol 20 mg, formulated for the management of anxiety disorders, panic attacks, and certain cardiovascular conditions. Clonazepam, a benzodiazepine, exerts its therapeutic effects by enhancing the activity of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the central nervous system, thereby producing anxiolytic, anticonvulsant, and muscle relaxant properties. Propranolol, a non-selective beta-adrenergic blocker, reduces heart rate, myocardial contractility, and sympathetic nervous system activity, making it effective in controlling hypertension, angina, and tachyarrhythmias, as well as mitigating physical symptoms of anxiety such as tremors and palpitations. The combined action of these agents provides a synergistic effect, addressing both the psychological and somatic manifestations of anxiety and related disorders. Kiprop-C is indicated for patients requiring both anxiolytic and beta-blocker therapy, particularly in cases where anxiety is accompanied by cardiovascular symptoms. Caution is advised in patients with respiratory disorders, hepatic impairment, or a history of hypersensitivity to benzodiazepines or beta-blockers. Dosage should be individualized based on clinical response, and the medication should be used under strict medical supervision to avoid potential adverse effects such as sedation, bradycardia, hypotension, or withdrawal symptoms.